Genome & Company said that it would build a large-scale microbiome production facility in Fishers City, Indiana, U.S., through its local offshoot, List Biotherapeutics.

The company established List Biotherapeutics in October last year. Biotherapeutics plans to build a large-scale microbiome production facility in Fishers Life Science & Innovation Park located in Fishers City and create 210 new jobs.

Fishers City has provided the site for List Biotherapeutics’ microbiome production facility free of charge and plans to grant 50 percent cuts in property tax for 15 years after the company completes the construction of its plant.

Besides, the Indiana Economic Development Cor. (IEDC) and local power companies promised additional support such as facility usage fee reduction and tax deductions.

Genome & Company will operate its subsidiaries, List Labs and List Bio as separate corporations, letting them attract new investments through independent operation while maximizing mutual synergy by utilizing the strengths of each company.

“It is meaningful that the company could take the first step toward building a new factory in Fishers City after acquiring the management rights of List Labs, a U.S. microbiome contract development manufacturing organization (CDMO) firm, in September,” Genome & Company CEO Pae Ji-soo said. “We will spare no effort to become a fully integrated pharmaceutical company capable of both R&D and production.”

List Biotherapeutics CEO Cho Yong-wan also said, “Through the new plant, the company plans to start full-scale development and production of microbiome drugs.”

Through List Labs' experience and know-how acquired for over 40 years, List Biotherapeutics will leap forward as a leading microbiome CDMO company, Cho added.